Results 131 to 140 of about 143,588 (347)

DYNLL1 binds MRE11 to limit DNA end resection in BRCA1-deficient cells

Nature, 2018
Limited DNA end resection is the key to impaired homologous recombination in BRCA1-mutant cancer cells. Here, using a loss-of-function CRISPR screen, we identify DYNLL1 as an inhibitor of DNA end resection.
Y. He, K. Meghani, Marie-christine Caron, Chunyu Yang, Daryl A. Ronato, J. Bian, Anchal Sharma, Jessica M. Moore, Joshi Niraj, A. Detappe, John G Doench, G. Legube, D. Root, A. D’Andrea, P. Drané, S. De, P. Konstantinopoulos, J. Masson, Dipanjan Chowdhury   +18 more
semanticscholar   +1 more source

Precision Chemistry for Protein Lysine Modification

Chemistry – A European Journal, EarlyView.
Selective modification of lysine residues is challenging due to their similar intrinsic reactivity. Inspired by enzymatic recognition, ligand‐guided electrophiles enable site‐selective labeling and functionalization, while ligand‐guided catalyses achieve regioselective installation of bio‐relevant post‐translational modifications.
Mayu Onoda, Motomu Kanai
wiley   +1 more source

Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer

Annual Review of Cancer Biology, 2017
Germ-line and somatic mutations in genes that promote homology-directed repair (HDR), especially BRCA1 and BRCA2, are frequently observed in several cancers, in particular, breast and ovary but also prostate and other cancers.
Chun-Chin Chen, Weiran Feng, P. Lim, Elizabeth M. Kass, M. Jasin   +4 more
semanticscholar   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović, Ingrid Tomljanović, Wieke H. Grievink, Diana R. Pereira, Michelle Osse, Peter van Balen, Maria J. Juachon, Marieke L. de Kam, Lisa Pagan, Manon A.A. Jansen, Matthijs Moerland, Jacobus J. Bosch   +11 more
wiley   +1 more source

BRCA1 polymorphisms [PDF]

British Journal of Cancer, 1997
Campbell, IG, Schroff, R, Englefield, P, Eccles, DM   +3 more
openaire   +3 more sources

Exome Sequencing–Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants

JAMA Network Open, 2018
Key Points Question Can population-level genomic screening identify those at risk for disease? Findings In this cross-sectional study of an unselected population cohort of 50 726 adults who underwent exome sequencing, pathogenic and likely pathogenic ...
Kandamurugu Manickam, A. Buchanan, Marci L. B. Schwartz, M. Hallquist, Janet L. Williams, A. Rahm, H. Rocha, J. Savatt, Alyson Evans, Loren Butry, Amanda L. Lazzeri, D’Andra M. Lindbuchler, Carroll N. Flansburg, R. Leeming, V. Vogel, Matthew S. Lebo, H. Mason-Suares, Derick Hoskinson, N. Abul-Husn, F. Dewey, J. Overton, J. Reid, A. Baras, H. Willard, Cara Mccormick, Sarath Babu Krishna Murthy, Dustin N. Hartzel, Korey A. Kost, Daniel R. Lavage, A. Sturm, Lauren R. Frisbie, T. Person, R. Metpally, Monica A. Giovanni, L. Lowry, J. Leader, M. Ritchie, D. Carey, A. Justice, H. L. Kirchner, W. Faucett, Marc S. Williams, David H. Ledbetter, M. Murray   +43 more
semanticscholar   +1 more source

Efficacy of Next-Generation Sequencing in Identifying Genetic Markers for Prostate Cancer Risk

Journal of Pharmacy and Bioallied Sciences
Background: Prostate cancer is one of the most prevalent cancers among men worldwide. The identification of genetic markers that contribute to the risk of prostate cancer can significantly enhance early diagnosis and personalized treatment strategies ...
Fahad H. Alaithan, Raghad H. Alaithan, Tauheed Ahmed   +2 more
doaj   +1 more source

BRCA1- and BRCA2-deficient mES cells are hypersensitive to olaparib and veliparib but not BSI-201.

, 2016
The clonogenic survival assays of wild-type, Brca1-/- 236.44 and Brca2lex1/lex2 mES cells following treatment with olaparib, veliparib and BSI-201. BRCA1- and BRCA2-deficient cells were extremely sensitive to olaparib and veliparib as compared to wild ...
Shuhei Ito (3151281), Mary Ellen Moynahan (111580), Maria Jasin (47165), Conleth G. Murphy (3151284), Ekaterina Doubrovina (3151287)   +4 more
core   +1 more source

The Diagnostic Value of Immunohistochemistry and Biomarkers in the Diagnosis of Mesothelioma in Pleural/Peritoneal Effusions

Diagnostic Cytopathology, EarlyView.
ABSTRACT Background Mesothelioma is a rare tumor that arises from the serosal cells lining the serous cavities, most commonly the pleura followed by the peritoneum. Presenting symptoms include pleuritic pain and bloody effusions that recur. Although cytologic analysis cannot determine the mesothelial subtype or in situ from invasive disease, the ...
Suzanne M. Selvaggi
wiley   +1 more source

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers

Nature Communications, 2017
Complete loss of BRCA1 or BRCA2 function is associated with sensitivity to DNA damaging agents. However, not all BRCA1 and BRCA2 germline mutation-associated tumors respond.
K. Maxwell, B. Wubbenhorst, Brandon M. Wenz, Daniel De Sloover, J. Pluta, Lyndsey Emery, A. Barrett, A. Kraya, Ioannis Anastopoulos, Shun Yu, Yuchao Jiang, Hao Chen, Nancy R. Zhang, Nicole M. Hackman, K. D’Andrea, R. Daber, J. Morrissette, N. Mitra, M. Feldman, S. Domchek, K. Nathanson   +20 more
semanticscholar   +1 more source